Gilead Sciences Q2 EPS Forecast Raised by Zacks Research

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities research analysts at Zacks Research boosted their Q2 2026 earnings per share (EPS) estimates for Gilead Sciences in a research note issued to investors on Friday, April 4th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will earn $1.84 per share for the quarter, up from their previous forecast of $1.83. The consensus estimate for Gilead Sciences' current full-year earnings is $7.95 per share. Zacks Research also issued estimates for Gilead Sciences' Q4 2026 earnings at $2.29 EPS, FY2026 earnings at $8.02 EPS, Q1 2027 earnings at $1.88 EPS and FY2027 earnings at $8.62 EPS.

A number of other equities analysts also recently issued reports on the company. Wells Fargo & Company raised their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Bank of America boosted their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. increased their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $105.12.

Remove Ads

Gilead Sciences Trading Up 2.2 %

GILD traded up $2.23 during midday trading on Monday, hitting $103.63. 8,683,683 shares of the company were exchanged, compared to its average volume of 7,493,897. The firm's 50 day moving average price is $108.34 and its 200-day moving average price is $96.79. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $119.96. The firm has a market capitalization of $129.04 billion, a P/E ratio of 280.08, a P/E/G ratio of 0.71 and a beta of 0.32. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were paid a $0.79 dividend. The ex-dividend date was Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 3.05%. Gilead Sciences's dividend payout ratio is 854.05%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares in the company, valued at $19,977,938.37. This represents a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 302,785 shares of company stock worth $30,503,250 over the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors have recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new position in Gilead Sciences in the fourth quarter worth $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the 4th quarter valued at $29,000. Crews Bank & Trust purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at $31,000. Finally, Stephens Consulting LLC raised its stake in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares during the period. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.